Author:
Perz J B,Giles C,Szydlo R,O'Shea D,Sanz J,Chaidos A,Wagner S,Davis J,Loaiza S,Marin D,Apperley J,Olavarria E,Rahemtulla A,Lampert I,Naresh K,Samson D,MacDonald D,Kanfer E J
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference30 articles.
1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. German Hodgkin's Lymphoma Study Group; lymphoma working party of the European group for blood and marrow transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.
2. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed or resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054.
3. Carella A, Carlier P, Congiu A, Occhini D, Meloni G, Anselmo AP et al. Nine years’ experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report. Leukemia 1991; 5 (Suppl 1): 68–71.
4. Carella AM, Prencipe E, Pungolino E, Lerma E, Frassoni F, Rossi E et al. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymph 1996; 21: 63–70.
5. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997; 3: 98–106.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献